Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9HPW3)

• Drug Name: Exemestane Drug Info
• Synonyms: Aromasil; Aromasin; Aromasine; EXE; Exemestance; Exemestano; Exemestanum; Nikidess; Pfizer brand of exemestane; Curator_000009; Fce 24304; Aromasin (TN); Aromasin, Exemestane; Exemestano [INN-Spanish]; Exemestanum [INN-Latin]; FCE-24304; PNU-155971; Exemestane [USAN:INN:BAN]; Exemestane (JAN/USP/INN); (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione; 6-Methylenandrosta-1,4-diene-3,17-dione; 6-Methyleneandrosta-1,4-diene-3,17-dione; 6-methylideneandrosta-1,4-diene-3,17-dione

Indication

Disease Entry	ICD 11	Status	REF
Hormonally-responsive breast cancer	2C60-2C65	Approved	[1]
Male breast carcinoma		Investigative	[2]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 60198
  ChEBI ID: CHEBI:4953
  CAS Number: CAS 107868-30-4
  TTD Drug ID: DM9HPW3
  INTEDE Drug ID: DR0675
  ACDINA Drug ID: D00261

Molecule-Related Drug Atlas

Drug(s) Targeting Aromatase (CYP19A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anastrozole	DMNP60F	Breast cancer	2C60-2C65	Approved	[10]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[3]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[11]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[12]
Testolactone	DMVY4GN	Breast cancer	2C60-2C65	Approved	[13]
LIAROZOLE	DM4OYXE	Dermatological disease	DA24.Y	Phase 2/3	[14]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[15]
BGS-649	DMO4MNQ	Endometriosis	GA10	Phase 2	[16]
NARINGENIN	DMHAZLM	N. A.	N. A.	Phase 1	[14]
FORMESTANE	DMWIDJK	Breast cancer	2C60-2C65	Withdrawn from market	[17]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[9]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[66]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[67]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[68]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[67]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[69]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[70]
Bifonazole	DM3KN7V	Fungal infection	1F29-1F2F	Approved	[71]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[72]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[67]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[18]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[19]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[20]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[21]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[22]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[23]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[24]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[25]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[19]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[26]

Drug(s) Affected By Adenylate kinase isoenzyme 1 (AK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[6]
Anastrozole	DMNP60F	Breast cancer	2C60-2C65	Approved	[6]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[6]
Selenium	DM25CGV	N. A.	N. A.	Approved	[27]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[29]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[30]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[30]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[31]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[32]

Drug(s) Affected By Trefoil factor 1 (TFF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[33]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[34]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[35]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[36]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[37]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[38]
Reserpine	DM6VM38	Hypertension	BA00-BA04	Approved	[35]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[39]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[40]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[41]

Drug(s) Affected By Progesterone receptor (PGR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[42]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[43]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[44]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[45]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[46]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[47]
Goserelin	DMAT8CG	Breast cancer	2C60-2C65	Approved	[48]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[49]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[50]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[51]

Drug(s) Affected By Myb-related protein B (MYBL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[52]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[53]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[54]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[55]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[56]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[57]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[54]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[58]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[50]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[59]

Drug(s) Affected By Androgen receptor (AR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[60]
Nilutamide	DMFN07X	Prostate cancer	2C82.0	Approved	[60]
Hydroxyflutamide	DMGIZF5	Prostate cancer	2C82.0	Approved	[60]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[61]
Bicalutamide	DMZMSPF	Prostate cancer	2C82.0	Approved	[62]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[42]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[8]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[63]
Selenium	DM25CGV	N. A.	N. A.	Approved	[64]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[65]

Drug(s) Affected By Amphiregulin (AREG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[73]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[74]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[75]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[76]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[77]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[78]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[79]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[55]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[56]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[80]

Drug(s) Affected By 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 (PLCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[81]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[82]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[83]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[84]
Ibrutinib	DMHZCPO	Mantle cell lymphoma	2A85.5	Approved	[85]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[86]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[86]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[87]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[88]

Drug(s) Affected By Homeobox protein Hox-D11 (HOXD11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[31]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[89]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[90]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[5]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[91]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[92]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[93]

Drug(s) Affected By Pituitary adenylate cyclase-activating polypeptide type I receptor (ADCYAP1R1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[94]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[56]
Haloperidol	DM96SE0	Delirium		Approved	[95]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[50]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[95]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[94]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[5]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[94]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[96]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[97]

Drug(s) Affected By Proliferation marker protein Ki-67 (MKI67)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[98]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[99]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[100]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[101]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[102]
Remdesivir	DMBFZ6L	Coronavirus Disease 2019 (COVID-19)	1D6Y	Approved	[103]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[55]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[104]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[105]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[56]

Drug(s) Affected By Kallikrein-7 (KLK7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[102]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[40]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[106]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[107]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[108]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[5]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[92]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[93]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[109]

Drug(s) Affected By Disabled homolog 2 (DAB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[34]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[41]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[110]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[111]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[112]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[113]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[50]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[29]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[114]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[115]

Drug(s) Affected By CD83 antigen (CD83)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[116]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[117]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[41]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[101]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[82]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[118]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[119]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[120]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[121]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[117]

Drug(s) Affected By Unconventional myosin-IXb (MYO9B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[122]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[121]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[50]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[29]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[123]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[124]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[93]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[100]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[100]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[125]

Drug(s) Affected By RRP12-like protein (RRP12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[99]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[100]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[126]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[127]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[128]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[128]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[128]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[29]

Drug(s) Affected By Dynein axonemal assembly factor 9 (DNAAF9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[50]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[130]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[5]
Afimoxifene	DMFORDT	Breast cancer	2C60-2C65	Phase 2	[131]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[129]

Drug(s) Affected By E3 ubiquitin-protein ligase RNF123 (RNF123)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[50]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[29]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[132]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[130]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[133]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[134]

Drug(s) Affected By Osteopetrosis-associated transmembrane protein 1 (OSTM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[41]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[135]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[126]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[136]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[137]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[31]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[138]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[139]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[140]

Drug(s) Affected By Glypican-2 (GPC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[141]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[142]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[124]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[91]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[88]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[143]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[144]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[145]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 14 (TNFRSF14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[41]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[146]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[147]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[55]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[148]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[50]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[149]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[150]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[151]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[31]

Drug(s) Affected By Integrator complex subunit 4 (INTS4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[152]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[32]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[5]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[153]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[93]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[152]

Drug(s) Affected By Inositol polyphosphate 5-phosphatase K (INPP5K)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[27]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[154]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[50]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[29]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[130]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[88]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[27]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[144]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[155]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[145]

Drug(s) Affected By ATP-binding cassette sub-family G member 4 (ABCG4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[156]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[141]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[89]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[93]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[144]
acetaldehyde	DMJFKG4	Discovery agent	N.A.	Investigative	[157]

Drug(s) Affected By TRIO and F-actin-binding protein (TRIOBP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[41]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[120]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[50]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[158]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[132]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[159]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[108]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[5]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[93]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[100]

Drug(s) Affected By TBC1 domain family member 17 (TBC1D17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[56]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[50]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[29]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[141]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[160]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[161]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[130]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[134]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[100]

Drug(s) Affected By Kinesin-like protein KIF13B (KIF13B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[162]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[50]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[29]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[30]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[89]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[34]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[132]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[163]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[130]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[106]

Drug(s) Affected By Transcription factor COE1 (EBF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[126]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[94]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[164]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[165]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[89]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[130]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[94]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[93]
THAPSIGARGIN	DMDMQIE	N. A.	N. A.	Preclinical	[166]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[97]

Drug(s) Affected By Meteorin (METRN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[126]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[50]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[167]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[32]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[89]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[94]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[93]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[144]
PMID27336223-Compound-5	DM6E50A	N. A.	N. A.	Patented	[167]

Drug(s) Affected By Solute carrier family 13 member 4 (SLC13A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[168]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[124]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[91]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[93]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[169]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aromatase (CYP19A1)	TTSZLWK	CP19A_HUMAN	Inhibitor	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 (PLCG2)	OTGVC9MY	PLCG2_HUMAN	Gene/Protein Processing	[5]
Adenylate kinase isoenzyme 1 (AK1)	OT614AR3	KAD1_HUMAN	Drug Response	[6]
Amphiregulin (AREG)	OTJFOR67	AREG_HUMAN	Gene/Protein Processing	[7]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Protein Interaction/Cellular Processes	[8]
Aromatase (CYP19A1)	OTZ6XF74	CP19A_HUMAN	Gene/Protein Processing	[9]
ATP-binding cassette sub-family G member 4 (ABCG4)	OT2XJIOG	ABCG4_HUMAN	Gene/Protein Processing	[5]
CD83 antigen (CD83)	OT1V4WQF	CD83_HUMAN	Gene/Protein Processing	[5]
Disabled homolog 2 (DAB2)	OTRMQTMZ	DAB2_HUMAN	Gene/Protein Processing	[5]
Dynein axonemal assembly factor 9 (DNAAF9)	OTTKWWQU	DAAF9_HUMAN	Gene/Protein Processing	[5]
E3 ubiquitin-protein ligase RNF123 (RNF123)	OTL59S8J	RN123_HUMAN	Gene/Protein Processing	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7073).
• [2] Exemestane FDA Label
• [3] Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
• [4] In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17beta-dihydroexemestane. Pharmacol Res Perspect. 2017 Apr 27;5(3):e00314.
• [5] Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane. Bone. 2007 Apr;40(4):876-87. doi: 10.1016/j.bone.2006.11.029. Epub 2006 Dec 28.
• [6] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [7] Characterization of the weak estrogen receptor alpha agonistic activity of exemestane. Breast Cancer Res Treat. 2009 Aug;116(3):461-70. doi: 10.1007/s10549-008-0151-x. Epub 2008 Aug 3.
• [8] Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. Toxicology. 2017 Jun 15;385:48-58. doi: 10.1016/j.tox.2017.05.001. Epub 2017 May 4.
• [9] Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005 Apr 15;11(8):2809-21. doi: 10.1158/1078-0432.CCR-04-2187.
• [10] Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
• [11] Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45.
• [12] Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9.
• [13] Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.
• [14] Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
• [15] Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032111)
• [17] The taiwaniaquinoids: a review. J Nat Prod. 2010 Feb 26;73(2):284-98.
• [18] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [19] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [20] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [21] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [22] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [23] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [24] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [25] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [26] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [27] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [28] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [29] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [30] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [31] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [32] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [33] Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int J Cancer. 2004 Mar 20;109(2):167-73. doi: 10.1002/ijc.11720.
• [34] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [35] Evaluation of an imaging-based in vitro screening platform for estrogenic activity with OECD reference chemicals. Toxicol In Vitro. 2022 Jun;81:105348. doi: 10.1016/j.tiv.2022.105348. Epub 2022 Mar 18.
• [36] Estrogenic activities of Ginkgo biloba extracts. Life Sci. 2004 Jan 30;74(11):1325-35. doi: 10.1016/j.lfs.2003.06.045.
• [37] Tartrazine and sunset yellow are xenoestrogens in a new screening assay to identify modulators of human oestrogen receptor transcriptional activity. Toxicology. 2012 Aug 16;298(1-3):40-51. doi: 10.1016/j.tox.2012.04.014. Epub 2012 May 3.
• [38] Arsenic induces functional re-expression of estrogen receptor by demethylation of DNA in estrogen receptor-negative human breast cancer. PLoS One. 2012;7(4):e35957. doi: 10.1371/journal.pone.0035957. Epub 2012 Apr 27.
• [39] Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model. Toxicol Sci. 2005 Feb;83(2):257-63.
• [40] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [41] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [42] Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol. 2002 Jan;80(1):61-70. doi: 10.1016/s0960-0760(01)00173-x.
• [43] Conception and pharmacodynamic profile of drospirenone. Steroids. 2003 Nov;68(10-13):891-905. doi: 10.1016/j.steroids.2003.08.008.
• [44] Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients. Int J Oncol. 2000 Nov;17(5):991-1000. doi: 10.3892/ijo.17.5.991.
• [45] Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells. Oncogene. 2005 Jun 23;24(27):4388-400. doi: 10.1038/sj.onc.1208623.
• [46] Tibolone and its metabolites enhance tissue factor and PAI-1 expression in human endometrial stromal cells: Evidence of progestogenic effects. Steroids. 2005 Nov;70(12):840-5. doi: 10.1016/j.steroids.2005.04.010.
• [47] Expression of estrogen-, progesterone-, and androgen-responsive genes in MCF-7 and MDA-MB-231 cells treated with o,p'-DDT, p,p'-DDT, or endosulfan. J Biochem Mol Toxicol. 2021 Jun;35(6):1-8. doi: 10.1002/jbt.22773. Epub 2021 Mar 16.
• [48] A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. Eur J Obstet Gynecol Reprod Biol. 2007 Nov;135(1):94-103. doi: 10.1016/j.ejogrb.2006.07.042. Epub 2006 Sep 14.
• [49] Serum free BG-1 cell proliferation assay: a sensitive method for determining organochlorine pesticide estrogen receptor activation at the nanomolar range. Toxicol In Vitro. 2006 Apr;20(3):382-94. doi: 10.1016/j.tiv.2005.08.016. Epub 2005 Oct 19.
• [50] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [51] Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers. Clin Cancer Res. 2004 Dec 15;10(24):8163-9.
• [52] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [53] Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma. Eur J Pharmacol. 2002 Feb 1;436(1-2):7-13. doi: 10.1016/s0014-2999(01)01577-1.
• [54] Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci. 2003 Aug 15;73(13):1705-19. doi: 10.1016/s0024-3205(03)00515-0.
• [55] Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
• [56] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [57] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [58] Inter-laboratory comparison of human renal proximal tubule (HK-2) transcriptome alterations due to Cyclosporine A exposure and medium exhaustion. Toxicol In Vitro. 2009 Apr;23(3):486-99.
• [59] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [60] TBECH, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer. Toxicol Appl Pharmacol. 2016 Sep 15;307:91-101. doi: 10.1016/j.taap.2016.07.018. Epub 2016 Jul 27.
• [61] Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
• [62] Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate. 2005 Nov 1;65(3):268-75. doi: 10.1002/pros.20282.
• [63] Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
• [64] Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004 Jan 1;64(1):19-22. doi: 10.1158/0008-5472.can-03-2789.
• [65] Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals. Toxicology. 2004 Feb 15;195(2-3):177-86. doi: 10.1016/j.tox.2003.09.012.
• [66] Cannabidiol (CBD) but not tetrahydrocannabinol (THC) dysregulate in vitro decidualization of human endometrial stromal cells by disruption of estrogen signaling. Reprod Toxicol. 2020 Apr;93:75-82. doi: 10.1016/j.reprotox.2020.01.003. Epub 2020 Jan 14.
• [67] Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay. Toxicol In Vitro. 2015 Oct;29(7):1729-35.
• [68] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [69] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [70] Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 10;48(5):1563-75.
• [71] Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Endocr Res. 2004 Aug;30(3):387-94.
• [72] Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biochem Mol Biol. 1999 Dec 31;71(5-6):223-30.
• [73] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [74] Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. J Soc Gynecol Investig. 2005 Oct;12(7):e55-67.
• [75] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [76] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [77] Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. Surgery. 2005 Sep;138(3):415-21. doi: 10.1016/j.surg.2005.06.030.
• [78] Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006 Apr;126(4):732-9. doi: 10.1038/sj.jid.5700202.
• [79] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [80] Amphiregulin is a vitamin D3 target gene in squamous cell and breast carcinoma. Biochem Biophys Res Commun. 2001 Mar 9;281(4):1051-6. doi: 10.1006/bbrc.2001.4466.
• [81] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [82] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [83] Arsenic trioxide-mediated antiplatelet activity: pivotal role of the phospholipase C gamma 2-protein kinase C-p38 MAPK cascade. Transl Res. 2010 Feb;155(2):97-108. doi: 10.1016/j.trsl.2009.08.005. Epub 2009 Sep 15.
• [84] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [85] Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. 2015 Sep 24;126(13):1565-74.
• [86] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [87] RNA sequence analysis of inducible pluripotent stem cell-derived cardiomyocytes reveals altered expression of DNA damage and cell cycle genes in response to doxorubicin. Toxicol Appl Pharmacol. 2018 Oct 1;356:44-53.
• [88] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [89] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [90] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [91] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [92] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [93] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [94] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [95] Neuroleptic Drugs and PACAP Differentially Affect the mRNA Expression of Genes Encoding PAC1/VPAC Type Receptors. Neurochem Res. 2017 Apr;42(4):943-952. doi: 10.1007/s11064-016-2127-2. Epub 2016 Nov 30.
• [96] Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen. 2014 Dec;775-776:48-54. doi: 10.1016/j.mrgentox.2014.10.011. Epub 2014 Nov 4.
• [97] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [98] Effect of menstrual cycle and hormonal treatment on ki-67 and bcl-2 expression and adenomyosis. Gynecol Endocrinol. 2005 Mar;20(3):127-31. doi: 10.1080/09513590400021086.
• [99] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [100] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [101] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [102] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [103] An in vitro study on anti-carcinogenic effect of remdesivir in human ovarian cancer cells via generation of reactive oxygen species. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221089257. doi: 10.1177/09603271221089257.
• [104] Mitophagy inhibits proliferation by decreasing cyclooxygenase-2 (COX-2) in arsenic trioxide-treated HepG2 cells. Environ Toxicol Pharmacol. 2016 Jul;45:212-21.
• [105] Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC. Chem Biol Interact. 2021 Nov 1;349:109652. doi: 10.1016/j.cbi.2021.109652. Epub 2021 Sep 11.
• [106] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [107] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [108] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [109] Cellular reactions to long-term volatile organic compound (VOC) exposures. Sci Rep. 2016 Dec 1;6:37842. doi: 10.1038/srep37842.
• [110] Constitutive gene expression predisposes morphogen-mediated cell fate responses of NT2/D1 and 27X-1 human embryonal carcinoma cells. Stem Cells. 2007 Mar;25(3):771-8. doi: 10.1634/stemcells.2006-0271. Epub 2006 Nov 30.
• [111] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [112] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [113] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [114] Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
• [115] Toxicoproteomics reveals an effect of clozapine on autophagy in human liver spheroids. Toxicol Mech Methods. 2023 Jun;33(5):401-410. doi: 10.1080/15376516.2022.2156005. Epub 2022 Dec 19.
• [116] Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
• [117] Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006 Mar;79(3):529-38. doi: 10.1189/jlb.0205064. Epub 2005 Dec 30.
• [118] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [119] Vitamin D Counteracts an IL-23-Dependent IL-17A(+)IFN-(+) Response Driven by Urban Particulate Matter. Am J Respir Cell Mol Biol. 2017 Sep;57(3):355-366. doi: 10.1165/rcmb.2016-0409OC.
• [120] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [121] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [122] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [123] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [124] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [125] Characterization of the Molecular Alterations Induced by the Prolonged Exposure of Normal Colon Mucosa and Colon Cancer Cells to Low-Dose Bisphenol A. Int J Mol Sci. 2022 Oct 1;23(19):11620. doi: 10.3390/ijms231911620.
• [126] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [127] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [128] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [129] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [130] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [131] Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators. Mol Endocrinol. 2010 Jan;24(1):33-46.
• [132] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [133] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [134] Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018 Nov;121:214-223. doi: 10.1016/j.fct.2018.08.034. Epub 2018 Aug 26.
• [135] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [136] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [137] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [138] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [139] Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells. Toxicology. 2015 Feb 3;328:102-11. doi: 10.1016/j.tox.2014.12.018. Epub 2014 Dec 18.
• [140] Application of the adverse outcome pathway concept for investigating developmental neurotoxicity potential of Chinese herbal medicines by using human neural progenitor cells in vitro. Cell Biol Toxicol. 2023 Feb;39(1):319-343. doi: 10.1007/s10565-022-09730-4. Epub 2022 Jun 15.
• [141] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [142] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [143] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [144] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [145] A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling. PLoS One. 2017 May 25;12(5):e0178302. doi: 10.1371/journal.pone.0178302. eCollection 2017.
• [146] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [147] Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
• [148] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [149] Effects of folate deficiency on gene expression in the apoptosis and cancer pathways in colon cancer cells. Carcinogenesis. 2006 May;27(5):916-24. doi: 10.1093/carcin/bgi312. Epub 2005 Dec 16.
• [150] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [151] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [152] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [153] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [154] NGBR is required to ameliorate type 2 diabetes in mice by enhancing insulin sensitivity. J Biol Chem. 2021 Jan-Jun;296:100624. doi: 10.1016/j.jbc.2021.100624. Epub 2021 Apr 2.
• [155] Alternatives for the worse: Molecular insights into adverse effects of bisphenol a and substitutes during human adipocyte differentiation. Environ Int. 2021 Nov;156:106730. doi: 10.1016/j.envint.2021.106730. Epub 2021 Jun 27.
• [156] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [157] Transcriptome profile analysis of saturated aliphatic aldehydes reveals carbon number-specific molecules involved in pulmonary toxicity. Chem Res Toxicol. 2014 Aug 18;27(8):1362-70.
• [158] Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005 Jul;98(1):45-53. doi: 10.1016/j.ygyno.2005.04.010.
• [159] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [160] DNA methylation inhibits p53-mediated survivin repression. Oncogene. 2009 May 14;28(19):2046-50. doi: 10.1038/onc.2009.62. Epub 2009 Apr 13.
• [161] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [162] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [163] Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
• [164] In vitro assessment of drug-induced liver steatosis based on human dermal stem cell-derived hepatic cells. Arch Toxicol. 2016 Mar;90(3):677-89. doi: 10.1007/s00204-015-1483-z. Epub 2015 Feb 26.
• [165] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [166] Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
• [167] PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med. 2006 Oct 2;203(10):2351-62.
• [168] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [169] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.